

Elsevier Public Health Emergency Collection

Public Health Emergency COVID-19 Initiative

Pharmacol Res. 2020 Jul; 157: 104837.

PMCID: PMC7175911

Published online 2020 Apr 22. doi: [10.1016/j.phrs.2020.104837](https://doi.org/10.1016/j.phrs.2020.104837)

PMID: [32334052](https://pubmed.ncbi.nlm.nih.gov/32334052/)

Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection

[Roberto Maggio](#)*

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy

[Giovanni U. Corsini](#)

Former Professor of Pharmacology, School of Medicine, University of Pisa, Italy

Roberto Maggio: roberto.maggio@univaq.it; Giovanni U. Corsini: gucorsini@tiscali.it

*Corresponding author. roberto.maggio@univaq.it

Received 2020 Mar 26

[Copyright](#) © 2020 Elsevier Ltd. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Dear Editor,

Bromhexine is an over-the-counter mucolytic cough suppressant that was introduced in 1963 under the trademark of Bisolvon®. It is a widely prescribed drug for treatment of a range of respiratory conditions, mainly those associated with a disturbance of mucus secretion, and it is well tolerated and safe. Chemical library screening for discovery of suppressors of prostate cancer metastasis identified bromhexine as a potent and selective inhibitor of the TMPRSS2 (Transmembrane Protein Serine 2) protease displaying an IC₅₀ of 0.75 µM [¹]. This is important since TMPRSS2 is an androgen regulated cell-surface serine protease that belongs to the very few trypsin-like proteases expressed in the human respiratory tract. It plays a role in the proteolytic activation and invasion of the human airway epithelium by influenza [²] as well as SARS-CoV and MERS [³] viruses.

The spread of the COVID-19 coronavirus pandemic is a major crisis of public health and has stimulated intensive efforts to find treatments active against the SARS-CoV-2 virus. Hoffmann et al. [⁴]

proposed the TMPRSS2 serine protease inhibitor camostat mesylate [5], a drug approved in Japan for use in chronic pancreatitis, for off-label treatment of SARS-CoV-2-infected patients. Their proposal is grounded in the finding that SARS-CoV-2 cell entry depends on binding of the viral spike (S) protein to cellular angiotensin converting enzyme 2 receptor and priming of the S protein by host cell TMPRSS2 protease [4]. Hoffmann's study indicated that cleavage of the viral S protein by TMPRSS2 protease occurs at S1/S2 arginine rich multibasic site: this is prevented by camostat mesylate which accordingly inhibits the entry of SARS-CoV-2 virus into Calu-3 lung cell lines and primary human airway epithelial cells. Furthermore, based on studies of influenza and other coronaviruses, TMPRSS2 may also regulate viral assembly in the Golgi apparatus and release of SARS-CoV-2 from the plasma membrane as previously suggested by Shen et al. [6].

The interaction of bromhexine with the TMPRSS2 enzyme together with its widespread clinical use and safety strongly support its evaluation in patients with SARS-CoV-2 infection, especially since the use of camostat mesylate is much less well established and very expensive. Indeed, bromhexine was already proposed by Shen et al. [6] as a candidate drug for treatment of SARS-CoV and MERS virus infections. Furthermore, pharmacokinetic data support the testing of bromhexine use for this indication since, in pulmonary and bronchial epithelial cells, it may reach concentrations 4 to 6-fold higher than those found in the plasma, high enough in principle to inhibit TMPRSS2 (bromhexine datasheet: <https://www.medsafe.govt.nz/Profs/Datasheet/b/BisolvonTabSol.pdf>).

Bromhexine hydrochloride is already in the pipeline for COVID-19 treatment, as a mucolytic medication for chest congestion and cough in patients with suspected and mild novel coronavirus pneumonia in China (ClinicalTrials.gov Identifier: NCT04273763). Recognition of the inhibitory effects of bromhexine at TMPRSS2 suggest its repurposing either as a treatment for patients with full-blown COVID-19 infections, or as a prophylactic agent to prevent the infection of high-risk subjects with SARS-CoV-2, which would also impede spreading of the virus. These observations warrant rigorous clinical trials of bromhexine, either alone or in association with other antiviral agents.

We thank Dr. Mark J. Millan for helpful discussions and comments on the letter.

Declaration of Competing Interest

We declare no competing interests.

References

1. Lucas J.M., Heinlein C., Kim T., Hernandez S.A., Malik M.S., True L.D., Morrissey C., Corey E., Montgomery B., Mostaghel E., Clegg N., Coleman I., Brown C.M., Schneider E.L., Craik C., Simon J.A., Bedalov A., Nelson P.S. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. *Cancer Discov.* 2014;4:1310–1325. <https://www.ncbi.nlm.nih.gov/pubmed/25122198/> [PMC free article] [PubMed] [Google Scholar]
2. Böttcher E., Matrosovich T., Beyerle M., Klenk H.D., Garten W., Matrosovich M. Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. *J. Virol.* 2006;80:9896–9898. <https://www.ncbi.nlm.nih.gov/pubmed/16973594/> [PMC free article] [PubMed] [Google Scholar]
3. Iwata-Yoshikawa N., Okamura T., Shimizu Y., Hasegawa H., Takeda M., Nagata N. TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection. *J. Virol.* 2019;93(6):e01815–01818. <https://www.ncbi.nlm.nih.gov/pubmed/30626688/>

[\[PMC free article\]](#) [\[PubMed\]](#) [\[Google Scholar\]](#)

4. Hoffmann M., Kleine-Weber H., Schroeder S., Hoffmann M., Kleine-Weber H., Schroeder S., Krüger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., Müller M.A., Drosten C., Pöhlmann S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell*. 2020 <https://www.ncbi.nlm.nih.gov/pubmed/32142651/> pii: S0092-8674(20)30229-4. [\[PMC free article\]](#) [\[PubMed\]](#) [\[Google Scholar\]](#)

5. Kawase M., Shirato K., van der Hoek L., Taguchi F., Matsuyama S. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. *J. Virol.* 2012;86:6537–6545. <https://www.ncbi.nlm.nih.gov/pubmed/224962166/> [\[PMC free article\]](#) [\[PubMed\]](#) [\[Google Scholar\]](#)

6. Shen L.W., Mao H.J., Wu Y.L., Tanaka Y., Zhang W. TMPRSS2: a potential target for treatment of influenza virus and coronavirus infections. *Biochimie.* 2017;142:1–10. <https://www.ncbi.nlm.nih.gov/pubmed/28778717/> [\[PMC free article\]](#) [\[PubMed\]](#) [\[Google Scholar\]](#)